Management of patients with advanced prostate cancer in the Asia Pacific region: ‘real‐world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017

Abstract

As the field continues to evolve, collaboration across the APAC region will be important to facilitate relevant research and collection and appraisal of data relevant to APAC populations. In the meantime, the APAC APCCC 2018 meeting highlighted the critical importance of a multidisciplinary team-based approach to treatment planning and care, delivery of best-practice care by clinicians with appropriate expertise, and the importance of patient information and support for informed patient choice.

Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients

“…The panel noted in the ideal world abiraterone and prednisolone should be added to ADT for patients presenting with HVD, however in the real world setting the majority indicated treatment would be either chemohormonal therapy or ADT (23). The Asian Pacific regional group indicated cost and access issues are major influences in the real-world application of best practices (24). An economic analysis of men with mCRPC prescribed enzalutatimde compared to abiraterone found the enzalutamide group had lower all-cause outpatient costs due to lower number of visits, and lower pharmacy costs (25).…”

A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer

“…Bicalutamide, an AR antagonist which binds to the AR block the action of androgens. It is widely used, especially in the Asia Pacific region as targeted therapy of prostate cancer and was used here in addition to temsirolimus [24,26]. Temsirolimus was used due to PTEN loss seen in genomic analysis.…”

Novel agents for metastatic hormone‐sensitive prostate cancer – a practice guide for urologists

“…We believe that urologists can and should re‐engage in this disease space. Indeed, in some parts of the world, they remain the principal practitioners involved in managing patients across the entire advanced prostate cancer disease spectrum, including the administration of chemotherapy . As the era of ADT monotherapy draws to a close, it is time urologists become familiar with prescribing novel agents.…”